**European approach for the medical management of mass radiation exposure**

Therapeutical management according to the European consensus conference*

Beyond the first 48 hrs, a second patient scoring is done by organs (Neurovascular, Hemopoiesis, Cutaneous, Gut) according to the METREPOL document** for therapeutical management and Multiple Organ Failure (MOF) prediction.

### Cytokines

**Score I: Monitoring. No cytokine**
- Outpatient clinical monitoring.
- Blood count: - every day for 6 days, - then once a week for 2 months.

**Score II: Cytokines (curative)**
- G-CSF + KGF should be used as early as possible for 14-21 days. TPO and agonists, EPO and stem cell factor questionable.
- Symptomatic treatment of gastrointestinal damage.
- If severe aplasia → Protected environment.
- Accidental radiation exposure is generally heterogeneous. Some under-exposed/protected regions of bone marrow can give rise to endogenous hematopoietic recovery.

**Score III: Cytokines (until reappraisal of score)**
- Palliative/Symptomatic treatment.
- Re-evaluation during the first week based on laboratory or clinical symptoms revealing irreversible organ damage or multi organ dysfunction.

**Hematopoietic stem cell (HSC) transplantation**

**Background**
- HSC transplantation is not an emergency.
- It is crucial to avoid GVHD in order not to compromise an endogenous recovery.
- If severe aplasia persists under cytokines for more than 14 days, the possibility of an hematopoietic stem cell (HSC) transplantation is discussed.

**Criteria to transplant**
- Severe marrow aplasia persisting 14 - 21 days.
- No residual hematopoiesis.
- No irreversible organ damage (GI tract, lungs...).

**Graft**
- Type of graft: - Bone marrow.
- Peripheral blood HSC (depleted or not).
- Cord blood.
- Donor in the following order of priority:
  - HLA-identical sibling or 7/8 matched.
  - HLA-identical unrelated donor or 9/10 matched.
  - Cord blood > 4/6 matched.
- Doses of cells to be grafted:
  - At least: - 2x10^6 CD34 cells.kg^-1 (peripheral blood);
  - 2x10^6 nucleated cells.kg^-1 (bone marrow);
  - 3x10^7 nucleated cells (cord blood).

**Conditioning and GVHD prevention**
- Non myelotoxic conditioning:
  - Fludarabine (30 mg.m^-2.d^-1 for 3 days) ± anti-lymphocyte globulins.
- GVHD prevention:
  - No Methotrexate.

---

**CONTACTS**

- R. Gourmelon (IRSN): patrick.gourmelon@irsn.fr
- N.C. Gorin (EBMT/IRSN): norbert-claude.gorin@sat.aphp.fr
- T. Meineke (Bundeswehr): ViktorMeineke@bundeswehr.org
- R. Powles (EBMT): myeloma@clara.co.uk
- D. Niederwieser (chair EBMT): dietger@medizin.uni-leipzig.de

---


The first 48 hours

**Life-threatening wounds and burns should be treated first**
Irradiation is not contamination – An irradiated person is not a source of radiation – In case of additional contamination, decontamination comes first

**Beware of Multiple Organ Failure (MOF)**
The severity of prodromal clinical features is of major importance.
- Extensive and immediate erythema.
- Early Transient Incapacitation Syndrome (temporary loss of consciousness).
- High fever.
- Hypotension.
- Immediate diarrhoea.

**Physical dosimetry**
- Inquiry: circumstances of the accident, source characteristics, source-victim geometry, duration of exposure, daily dose rate, shielding, homogeneous/heterogeneous irradiation.
- Labelling and storage of personal belongings and clothes, biological material (hair, nails).

**Urgent sampling**
- Blood cell counts (+ differentials) every 4-8 hours for the 1st 24 hours, 12-24 h after.
- Chromosome abberations on blood lymphocytes (biodosimetry) (15 ml + heparin).
- Red cell group typing.
- Store serum and cells or DNA for further analyses including HLA typing.
- Standard biochemistry + amylasemia.
- Blood (20 ml) to measure number of neutrons.
- Urine and faeces if radionuclide contamination is suspected.

**Primary scoring**
*Record all clinical symptoms on a date and hour-stamped chart*

<table>
<thead>
<tr>
<th>Symptom</th>
<th>Score I</th>
<th>Score II</th>
<th>Score III</th>
</tr>
</thead>
<tbody>
<tr>
<td>Average delay before symptoms appear</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cutaneous erythema</td>
<td>Less than 12 hours</td>
<td>0</td>
<td>+/-</td>
</tr>
<tr>
<td>Asthenia</td>
<td>+</td>
<td>++</td>
<td>+++; before 3rd hour</td>
</tr>
<tr>
<td>Nausea</td>
<td>++</td>
<td>+++</td>
<td>(+)</td>
</tr>
<tr>
<td>Vomiting per 24 hrs</td>
<td>Maximum 1</td>
<td>1 to 10</td>
<td>Above 10; intractable</td>
</tr>
<tr>
<td>Diarrhea / Number of stools per 24 hrs</td>
<td>Maximum 2 - 3; bulky</td>
<td>2 - 9; soft</td>
<td>Above 10; watery</td>
</tr>
<tr>
<td>Abdominal pain</td>
<td>Minimal</td>
<td>intense</td>
<td></td>
</tr>
<tr>
<td>Headaches</td>
<td>0</td>
<td>++</td>
<td>Excruaciung; Signs of intra-cranial HT</td>
</tr>
<tr>
<td>Temperature</td>
<td>Below 38°C</td>
<td>38 - 40°C</td>
<td></td>
</tr>
<tr>
<td>Blood pressure</td>
<td>Normal</td>
<td>Normal - Possible temporary decrease</td>
<td>Systolic below 80</td>
</tr>
<tr>
<td>Temporary loss of consciousness</td>
<td>0</td>
<td>0</td>
<td>+ / Coma</td>
</tr>
</tbody>
</table>

**Depletion of blood lymphocytes**

<table>
<thead>
<tr>
<th>Time (days)</th>
<th>Lymphocytes per µl</th>
</tr>
</thead>
<tbody>
<tr>
<td>0</td>
<td>Normal</td>
</tr>
<tr>
<td>1</td>
<td>Moderate</td>
</tr>
<tr>
<td>2</td>
<td>Severe</td>
</tr>
<tr>
<td>3</td>
<td>Critical</td>
</tr>
<tr>
<td>4</td>
<td>Lethal</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Injury</th>
<th>Time (days)</th>
<th>Lymphocytes per µl</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>24 hours</td>
<td>Above 1 500 / µl</td>
</tr>
<tr>
<td></td>
<td>48 hours</td>
<td>Above 1 500 / µl</td>
</tr>
</tbody>
</table>

**Outpatient monitoring**

**Hospitalisation for curative treatment**

**Hospitalisation (MOF predicted)**

Warning: the symptoms and values indicated above are reliable only in case the whole body or large parts of the body have been externally exposed to a high radiation dose delivered within few minutes or few hours.

Fill and fax MED A (radiation accident) to: (+33) 1 40 46 96 07

---

**Do not forget recording in parallel neutrophils and platelets**